Wavelength-Pharmaceuticals-Insert
X

Find Clinical Drug Pipeline Developments & Deals by Codagenix

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CDX-005

            Therapeutic Area: Infections and Infectious Diseases Product Name: CDX-005

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 18, 2020

            Details:

            CDX-005, is currently under safety and efficacy studies in animals and appears markedly attenuated compared to wild-type SARS-CoV-2. After successful completion of pre-clinical studies, CDX-005 will be manufactured by the Serum Institute and tested in a Phase I clinical trial.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Live-attenuated vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Vaccine

            Recipient: Serum Institute of India

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration February 14, 2020

            Details:

            Codagenix has designed multiple nCoV vaccine candidate genomes using its proprietary deoptimization technology. The vaccine viruses will then be grown and tested in vivo.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Respiratory syncytial virus vaccine

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Adjuvant Capital

            Deal Size: $20.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing January 13, 2020

            Details:

            The funds will be used to support the further clinical development of Codagenix's live attenuated RSV vaccine for the elderly.